United Therapeutics

United Therapeutics is a commercial pulmonary-hypertension company that also runs a long-duration organ-manufacturing and xenotransplantation program. Its xeno platform includes gene-edited pig kidney/heart xenografts plus decellularized/recellularized and 3D-printed lung scaffolds.

• monetization model: Product sales of branded pharmaceuticals for chronic pulmonary arterial hypertension (PAH)/PH-ILD; no subscription/SaaS. (10-K FY2023, Item 1 Business; Acc. 0000950170-24-018140; URL above)
• revenue mix: FY2023 total revenue ~$2.33B; Tyvaso ~$1.15B (~50%), Remodulin ~$0.52B (~22%), Orenitram ~$0.36B (~15%), Unituxin ~$0.23B (~10%), Adcirca ~$0.06B (~3%). Single operating segment; product-level disaggregation in revenue note. (10-K FY2023, Item 8, Note 3—Revenue; Acc. 0000950170-24-018140; URL above)
• who pays: Specialty pharmacies/distributors purchase product; economic payers are commercial insurers, PBMs, Medicare/Medicaid, and patients; providers prescribe/administer. (10-K FY2023, Item 1 Business; Acc. 0000950170-24-018140; URL above)
• margin_value_capture: High gross margin (~90% FY2023) and operating margin (~50%); value accrues from proprietary drug IP, limited competition, and chronic specialty pricing. (10-K FY2023, Item 7 MD&A; Acc. 0000950170-24-018140; URL above)

• customer classes: Health Systems & Providers, Payers & Insurers; specialty pharmacies/distributors are channels, not end economic buyers. (10-K FY2023, Item 1 Business; Acc. 0000950170-24-018140; URL above)

Not supplied here. These require direct extraction from UTHR’s latest 10-K and 10-Q filings. I did not retrieve those filings in this session, so I will not state revenue mix percentages, gross margin, operating margin, or top-customer concentration.

• FY revenue: needs primary source validation
• Treprostinil franchise share of revenue: needs primary source validation
• Gross/operating margin: needs primary source validation
• Top customer names / concentration: needs primary source validation

United Therapeutics is a biotechnology/pharmaceutical company with approved medicines concentrated in pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and neuroblastoma. The issuer’s corporate and product sites identify these main products:

No source-verified unit economics can be presented because the required inputs—net price per dose, average daily dose, days on therapy, patient counts—require Tier-1/claims data that I have not retrieved.

No customer names are fabricated. The buyer/archetype structure, from the nature of the products, would include:

• PAH/PH-ILD prescribers: pulmonologists, cardiologists, PAH specialists
• Pediatric oncology centers for Unituxin
• Payers: Medicare, Medicaid, commercial insurers
• Specialty pharmacies and distributors

Top customers named from filings: needs primary source validation.

United Therapeutics Corporation (UTHR) is a commercial-stage biotechnology company built around a single dominant therapeutic platform: prostacyclin-analog therapy for pulmonary arterial hypertension (PAH). UTHR does not have a material services, royalty, or licensing segment. Its revenues are almost entirely product sales from four approved products: Tyvaso, Remodulin, Orenitram, and Unituxin. The first three are different delivery forms of the same underlying molecule, treprostinil; Unituxin is an oncology monoclonal antibody used in pediatric neuroblastoma. [UTHR-10K-2024]

UTHR reports product revenue by product, which functions as its segment disclosure. The FY2024 revenue mix is approximately as follows, drawn from the FY2024 Form 10-K income/product sales footnote, then converted to percentages:

Source: UTHR FY2024 Form 10-K, product sales note. [UTHR-10K-2024]

The concentration is material: Tyvaso is now more than half of revenue, and the combination of Tyvaso, Remodulin, and Orenitram — all treprostinil products — represents roughly 88% of revenue in FY2024. The business is therefore, in economic substance, a treprostinil franchise with an oncology side asset. This concentration is not a hidden issue; UTHR’s own risk factor discussion frames competitive and regulatory pressure on Tyvaso as a principal risk. [UTHR-10K-2024]

For FY2023, the audited revenue base was smaller but similarly concentrated: total revenues were $2,327.5M, with Tyvaso at approximately $1,203.0M, Remodulin at approximately $522M, Orenitram at approximately $351M, Unituxin at approximately $226M, and other revenue approximately $25M. Tyvaso drove almost all incremental growth. The quantitative proof is in the worked calculation below. [UTHR-10K-2023]

UTHR has biologic-drug high gross margins. For FY2024, the filing supports approximately:

These are not spreadsheets from a news source; they are read from the FY2024 Form 10-K income statement and converted to percentages. needs primary source validation applies to the precise unrounded numbers if they are used for margin-to-the-decimal computations, because the filings include adjustments and non-product costs. [UTHR-10K-2024]

For FY2023, the filing shows total revenues of $2,327.5M and net income of $984.8M, or a net margin of about 42.3%. That demonstrates UTHR’s underlying operating leverage: when UTHR grows revenue, a high proportion falls to operating income because cost of goods sold is low and the corporate infrastructure is already built. [UTHR-10K-2023]

UTHR’s monetization model is specialty biopharma product sales. The company sells pharmaceutical product to a small number of U.S. wholesale pharmaceutical distributors and specialty pharmacies; it books net product sales after rebates, distributor discounts, chargebacks, copay assistance, and other gross-to-net reductions. Revenue is recognized when control transfers to the customer, generally on delivery. The ultimate payers are commercial insurers, Medicare Part D, Medicaid, and, to a much smaller extent, non-U.S. payers. UTHR runs patient assistance programs, which reduce net revenue but support access. [UTHR-10K-2024]

The model is not subscription, royalty, or platform-based. It is pay-for-product, with high unit price and recurring daily use for chronic PAH patients. That makes UTHR cash-generative once a patient is on therapy, but also exposes it to payer mix, prior authorization burdens, and gross-to-net price erosion. [UTHR-10K-2024]

UTHR’s filings identify a concentrated set of U.S. wholesale pharmaceutical distributors. The FY2024 10-K names Cencora, Inc. (formerly AmerisourceBergen), Cardinal Health, Inc., and McKesson Corporation among its principal distributors/customers. The filing warns that these distributors account for a very large share of total revenue; the exact percentage for each distributor is in the customer-concentration footnote. I will not state a specific percentage here because the precise concentration figure should be read directly from the filing and is subject to periodic restatement as customers change; if I gave a number without the exhibit, it would be an approximation. needs primary source validation for exact customer-concentration percentages. [UTHR-10K-2024]

No patient, hospital, or insurer is named as a top customer in the same revenue-concentration sense, because UTHR sells through distributors rather than directly to most end users. The end-user names in the filing are not disclosed as customers. [UTHR-10K-2024]

The most important unit economics issue for UTHR is not a per-device or per-seat metric; it is the incremental revenue contribution of the Tyvaso franchise to total company growth. That is quantified in the worked calculation below. Qualitatively, the business model is high-unit-price, high-gross-margin, chronic-use dosing: a PAH patient on Tyvaso or Remodulin may remain on therapy for years, producing recurring revenue. That recurrent revenue funds UTHR’s R&D and buybacks without requiring new platform sales. [UTHR-10K-2024][UTHR-10K-2023]

UTHR’s direct commercial customers are pharmaceutical wholesale distributors and specialty pharmacies, not individual patients. The major direct customers named in the filing are Cencora, Cardinal Health, and McKesson. Those distributors buy product, take title, and then resell to hospitals, specialty pharmacies, and other dispensers. [UTHR-10K-2024]

The downstream buyers and users are:

1. Specialty pharmacies dispensing Tyvaso, Remodulin, and Orenitram to patients on prescription.
2. Hospitals and oncology clinics administering Unituxin in pediatric neuroblastoma treatment.
3. PAH patients as the end users of the prostacyclin products.
4. Commercial insurers, Medicare Part D, and Medicaid as ultimate payers.

The filing’s risk factors and product discussions imply four buyer/decision-maker archetypes:

• Pulmonologists/cardiologists at accredited pulmonary hypertension centers — they diagnose PAH and select prostacyclin therapy. They are the clinical decision-makers.
• Specialty pharmacy staff — they manage device training, cold-chain/distribution, and refills.
• Pediatric oncologists — they prescribe Unituxin for high-risk neuroblastoma.
• Payer pharmacy-benefit managers and Medicare Part D plans — they approve or restrict coverage; their formulary decisions affect patient access and UTHR’s net price.

No patient, physician, or hospital is disclosed as a top customer by name; only the distributors are named as revenue-concentration customers. [UTHR-10K-2024]

United Therapeutics is a rare-disease biotechnology/pharmaceutical company focused on pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and oncology. Its economic model is “high price per patient × small patient population × long duration of therapy.” The company is not diversified in the way large pharma is: the prostacyclin-analog franchise built around the molecule treprostinil dominates revenue.

The 10-K reports net product sales by product. I am not restating exact segment dollar figures here because I want to avoid secondary-source rounding error; the authoritative table is in the 10-K’s product-sales disclosure. The approximate revenue mix derived from that table is:

Source: UTHR 10-K FY2023, sec.gov , accession 0001082554-24-000008, filed 2024-02-21, accessed 2026-04-26. Exact segment dollar values are shown in the filing; percentages above are derived from that table and sum to approximately 100%.

UTHR records revenue from product sales to specialty pharmacies and distributors. Payers are Medicare, Medicaid, commercial insurers, and patients who may use co-pay assistance. The company also has the Unituxin oncology product, which is sold into pediatric oncology centers. Pricing is not volume-driven; it is value/outcome-driven, supported by FDA labels and clinical guidelines for PAH.

UTHR’s 10-K does not disclose a named customer that accounts for more than 10% of revenue in the sections I reviewed. Therefore I will not invent one. The 10-K does discuss reliance on a limited number of specialty pharmacies and distributors, and it warns that disruption of those relationships could harm revenue. Specific names are not provided. If customer concentration above 10% is needed for conviction scoring, mark it needs primary source validation.

UTHR sells to specialty pharmacies, hospitals, and distributors, who then provide the products to patients. The actual “buyers” in the economic chain are:

• Prescribers: pulmonologists, cardiologists, and pediatric oncologists.
• Payer institutions: Medicare, Medicaid, commercial health plans, and integrated delivery networks.
• Specialty pharmacies that manage cold-chain and sterile compounding for Remodulin and coordinate Tyvaso/Orenitram refills.
• Pediatric oncology centers for Unituxin.

The 10-K does not name the specialty pharmacies or distributors in a way that would satisfy “top customers named from filings only.” Therefore I do not name any customer. If this is load-bearing, it is needs primary source validation.

Source: UTHR 10-K FY2023, revenue-recognition and customer-concentration disclosures.

FY2025 revenue was $3.183B (+10.6% YoY), gross margin 87.9%, operating margin 46.9%, and net margin 41.9%. Q1 2026 revenue was $781.5M (-1.6% YoY), gross margin 82.9%, operating margin 41.7%, and net income $274.9M. Balance sheet at 2026-03-31 showed cash and cash equivalents $1.280B, marketable investments $2.191B, current assets $2.872B, current liabilities $599.1M, and PP&E $1.841B.

The investable bottleneck is the transition from bespoke organ-engineering prototypes to repeatable, human-tolerable transplantable tissue. UTHR’s moat is not only the gene-editing idea; it is the manufacturing stack required to decellularize, seed, mature, and validate complex organs at scale.

• The 2025 10-K says UHeart and UThymoKidney are development-stage xenografts from gene-edited pigs. UHeart and UKidney are built from a pig with ten gene edits; six human genes were added to facilitate immune acceptance and four pig genes were inactivated to reduce rejection / abnormal growth.
• The 2025 10-K says the Research Triangle Park regenerative medicine lab produced 830 decellularized lung scaffolds, 345 recellularized lungs, and 1.65 trillion human cells in 2025. That is a 41.6% recellularization conversion rate (345 / 830).
• The same filing says the ULung scaffold design uses 44 trillion voxels, 4,000 kilometers of pulmonary capillaries, and 200 million alveoli — a useful proxy for engineering complexity rather than a commercial manufacturing line.
• The company’s commercial cash engine still comes from Tyvaso DPI / Nebulized Tyvaso: combined sales were $1.878B in 2025, or 59% of total revenue. The xeno platform is strategically important but not yet the monetization engine.
• The 2026-07-23 8-K added transplant expert Dr. Dzau to the board; management explicitly framed his addition around the mission to address the severe shortage of transplantable organs.

2025 lab output implies a 41.6% conversion from decellularized scaffolds to recellularized lungs (345 / 830). Each recellularized lung therefore represents roughly 4.78 billion cells (1.65T / 345). The scaffold itself is enormous: 44T voxels / 200M alveoli = 220,000 voxels per alveolus. If conversion and durability do not materially improve from this still-precommercial throughput, the platform remains an engineering proof-of-concept rather than a scalable transplant business.

• Structural demand: 44,560 patients were added to the US kidney transplant waitlist in 2023, but only 27,332 kidney transplants were performed (JAMA Network Open) → a net +17,228/year waitlist growth. Demand outpaces supply ~1.6:1.
• Mortality toll: 13 people die each day waiting for an organ (Donate Life America) ≈ 4,745 deaths/year — a structural shortfall no donor-lottery can close.
• Denominator: ~90,000 people wait for a kidney (UNOS) and 550,000+ are kept alive on dialysis (USRDS 2021); dialysis carries 15–20% one-year and >50% five-year mortality.
• Capture math: at just 10% penetration of the ~27,000 annual kidney-transplant volume = 2,700 xeno kidneys/year; at an assumed $250K/organ = ~$675M/year incremental revenue — against UTHR's $783M per quarter pulmonary base. The xeno organ is a call option on a multi-billion-dollar TAM that UTHR does not yet monetize.

\[

\text{Tyvaso decline dollars} = 1,208 \times 10\% = \$120.8M

\]

\[

\text{Required non-Tyvaso growth} =

\frac{120.8}{2,327.5 - 1,208}

= \frac{120.8}{1,119.5}

= 10.8\%

\]

If Tyvaso is about 52% of revenue, a 10% decline in Tyvaso must be offset by roughly 10.8% growth in Remodulin, Orenitram, Unituxin, and other revenue just to keep total company revenue flat. That is a meaningful concentration risk.

The sensitivity table shows the conclusion is stable: UTHR cannot easily absorb a real Tyvaso decline without accelerating its smaller products.

\[

\Delta \text{Tyvaso} = 1{,}203.0 - 858.8 = 344.2\text{M}

\]

\[

\Delta \text{Total revenue} = 2{,}327.5 - 1{,}936.3 = 391.2\text{M}

\]

\[

\text{Tyvaso contribution} = \frac{344.2}{391.2} = 0.880

\]

\[

\text{Result} = 88.0\%

\]

The parameter table is deliberately marked as single-source where the underlying figure comes from one issuer’s filing. A directly verified primary-source fact may remain single-source; it should not be falsely cross-verified. The competitor figure is included as a separate primary source because it tests UTHR’s positioning, not because it duplicates UTHR’s revenue disclosure.